Related Experiment Videos
Failure of nimodipine to prevent ischemic neuronal damage in rats
Abstract:
The efficacy of nimodipine in preventing ischemic brain injury was tested in rats subjected to a 20-minute period of high-grade forebrain ischemia by 4-vessel occlusion. Three minutes after restoration of circulation to the brain, an intravenous bolus of 5 micrograms/kg nimodipine or an equivalent amount of vehicle or saline was given, followed by continuous intravenous infusion of the respective solution at 1 microgram/kg/min for 2 hours. In a second series, a larger bolus (20 micrograms/kg of nimodipine) and longer infusion period (6 hours) were employed. Histopathology of the brain was evaluated blindly 72 hours later and graded on a conventional 3-point scale. There was no significant effect of treatment in either series. In the 6-hour series, the percent of cerebral hemispheres showing damage of Grades 2 or 3 in zone CA1 of the hippocampus and in the striatum, respectively, was 100 and 40% for the nimodipine-treated rats, 100 and 42% for rats receiving vehicle, and 75 and 25% for animals receiving saline. Thus, this study revealed no beneficial effect of nimodipine when given following a 20-minute period of severe forebrain ischemia.
Insights
Nimodipine did not prevent ischemic brain injury in rats after severe forebrain ischemia. This study found no beneficial effect of nimodipine in preventing brain damage following a 20-minute ischemic period.
Area of Science:
- Neuroscience
- Pharmacology
- Ischemic Stroke Research
Background:
- Ischemic brain injury is a significant cause of neurological damage.
- Nimodipine is a calcium channel blocker with potential neuroprotective properties.
- Previous research suggests nimodipine may be beneficial in certain ischemic conditions.
Purpose of the Study:
- To evaluate the efficacy of nimodipine in preventing ischemic brain injury in a rat model.
- To determine if nimodipine administration post-ischemia can mitigate neuronal damage.
Main Methods:
- Rats underwent a 20-minute forebrain ischemia via 4-vessel occlusion.
- Nimodipine or vehicle was administered intravenously shortly after reperfusion.
- Histopathological brain damage was assessed blindly 72 hours post-ischemia.
Main Results:
- Nimodipine treatment showed no significant protective effect against ischemic brain injury in either experimental series.
- In the longer treatment group, nimodipine-treated rats exhibited similar levels of hippocampal and striatal damage compared to vehicle and saline controls.
- Specifically, 100% of nimodipine-treated rats showed Grade 2 or 3 damage in hippocampal CA1 zone.
Conclusions:
- Nimodipine is not effective in preventing severe forebrain ischemic brain injury when administered after the ischemic event.
- The findings do not support the use of nimodipine for neuroprotection in this specific model of acute ischemic stroke.
- Further research may be needed to explore nimodipine's role in different ischemic scenarios or treatment timings.